SynthesisBMJ open2014
Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis.
Synthesis in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Global assessment of C-reactive protein and health-related outcomes: an umbrella review of evidence from observational studies and Mendelian randomization studies.European journal of epidemiology · 2021Pooled it
- Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review.Current neuropharmacology · 2018Pooled it
- A significant causal association between C-reactive protein levels and schizophrenia.Scientific reports · 2016Pooled it
- C-reactive protein in cardiovascular disease: clinical associations, conformation-dependent biology, and therapeutic perspectives.Frontiers in immunology · 2026Review
- Correlation between vascular adhesion protein-1 and major adverse cardiovascular events in patients with atrial fibrillation.Frontiers in cardiovascular medicine · 2025Article
- Post-stroke Arrhythmias: Performance of Brain-heart Crosstalk Networks.Current cardiology reviews · 2025Review
- Low-level auricular vagus nerve stimulation lowers blood pressure and heart rate in paroxysmal atrial fibrillation patients: a self-controlled study.Frontiers in neuroscience · 2025Article
- Impact of initial high sensitivity C-reactive protein on outcomes in nonvalvular atrial fibrillation: an observational study.Future cardiology · 2024Observational
- Association between Life's Essential 8 score and high-sensitivity C-reactive protein: A cross-sectional study from NHANES 2015-2018.Clinical cardiology · 2024Article
- Early Detection of Atrial Fibrillation in Chronic Obstructive Pulmonary Disease Patients.Medicina (Kaunas, Lithuania) · 2024Review
- Atrial Fibrillation Types and Chronic Kidney Disease are Independent Predictors of Atrial Fibrillation Recurrence After Radiofrequency Ablation.Therapeutics and clinical risk management · 2024Article
- The Role of Biochemical Cardiac Markers in Atrial Fibrillation.The Journal of innovations in cardiac rhythm management · 2023Review
- Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion.Biomedicines · 2023Review
- Features of Atrial Fibrillation Pathogenesis and Prognosis in Chronic Obstructive Pulmonary Patients during the COVID-19 Pandemic.Reviews in cardiovascular medicine · 2023Review
- Article
- Markers of Inflammation, Oxidative Stress, and Fibrosis in Patients with Atrial Fibrillation.Oxidative medicine and cellular longevity · 2022Article
- The Potential Prognostic, Diagnostic and Therapeutic Targets for Recurrent Arrhythmias in Patients with Coronary Restenosis and Reocclusions After Coronary Stenting.Current pharmaceutical design · 2022Article
- Review
- Review
- Influence of Inflammation and Atherosclerosis in Atrial Fibrillation.Current atherosclerosis reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe performed a systematic review and meta-analysis of studies on high-sensitivity C-reactive protein (hs-CRP) assays to see whether these tests are predictive of atrial fibrillation (AF) recurrence after cardioversion.
designSystematic review and meta-analysis. DATA SOURCES: PubMed, EMBASE and Cochrane databases as well as a hand search of the reference lists in the retrieved articles from inception to December 2013. STUDY ELIGIBILITY CRITERIA: This review selected observational studies in which the measurements of serum CRP were used to predict AF recurrence. An hs-CRP assay was defined as any CRP test capable of measuring serum CRP to below 0.6 mg/dL. PRIMARY AND SECONDARY OUTCOME MEASURES: We summarised test performance characteristics with the use of forest plots, hierarchical summary receiver operating characteristic curves and bivariate random effects models. Meta-regression analysis was performed to explore the source of heterogeneity.
resultsWe included nine qualifying studies comprising a total of 347 patients with AF recurrence and 335 controls. A CRP level higher than the optimal cut-off point was an independent predictor of AF recurrence after cardioversion (summary adjusted OR: 3.33; 95% CI 2.10 to 5.28). The estimated pooled sensitivity and specificity for hs-CRP was 71.0% (95% CI 63% to 78%) and 72.0% (61% to 81%), respectively. Most studies used a CRP cut-off point of 1.9 mg/L to predict long-term AF recurrence (77% sensitivity, 65% specificity), and 3 mg/L to predict short-term AF recurrence (73% sensitivity, 71% specificity).
conclusionshs-CRP assays are moderately accurate in predicting AF recurrence after successful cardioversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.